| Dr Paraschos Archontakis Barakakis, MD | |
|
46 Fairview Ave, Skowhegan, ME 04976-1481 | |
| (207) 474-5121 | |
| (207) 858-2415 |
| Full Name | Dr Paraschos Archontakis Barakakis |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 3 Years |
| Location | 46 Fairview Ave, Skowhegan, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457872269 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 010085752A (Indiana) | Secondary |
| 207R00000X | Internal Medicine | MD26930 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Redington Fairview General Hospital | Skowhegan, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Redington-fairview General Hospital | 9133018740 | 36 |
News Archive
Beagle Freedom Project, a national nonprofit based in Los Angeles, is continuing its mission to further reduce and replace animals in cruel experiences, because it believes that medical research can no longer rely on the use of these animals in controversial experiments.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.
Communications issues between the state agencies that administer the program and the federal exchange are interfering with the concept of one-stop shopping.
› Verified 5 days ago
| Entity Name | Redington-fairview General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174549133 PECOS PAC ID: 9133018740 Enrollment ID: O20040312000119 |
News Archive
Beagle Freedom Project, a national nonprofit based in Los Angeles, is continuing its mission to further reduce and replace animals in cruel experiences, because it believes that medical research can no longer rely on the use of these animals in controversial experiments.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.
Communications issues between the state agencies that administer the program and the federal exchange are interfering with the concept of one-stop shopping.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paraschos Archontakis Barakakis, MD Po Box 468, Skowhegan, ME 04976-0468 Ph: (207) 474-5121 | Dr Paraschos Archontakis Barakakis, MD 46 Fairview Ave, Skowhegan, ME 04976-1481 Ph: (207) 474-5121 |
News Archive
Beagle Freedom Project, a national nonprofit based in Los Angeles, is continuing its mission to further reduce and replace animals in cruel experiences, because it believes that medical research can no longer rely on the use of these animals in controversial experiments.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.
Communications issues between the state agencies that administer the program and the federal exchange are interfering with the concept of one-stop shopping.
› Verified 5 days ago
Oto Prokop, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 46 Fairview Ave Ste 111, Skowhegan, ME 04976 Phone: 207-474-0905 Fax: 207-474-6930 | |
Donna Conkling, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 46 Fairview Ave, Suite 111, Skowhegan, ME 04976 Phone: 207-474-0905 Fax: 207-474-6930 | |
Dr. Michael J Monzel, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 46 Fairview Ave Ste 221, Skowhegan, ME 04976 Phone: 207-474-6945 Fax: 207-474-6933 | |
Daniel Stevenson Stadler, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 23 Cedar Ridge Dr, Skowhegan, ME 04976 Phone: 207-474-9686 | |
Dr. Rajdeep Brar, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 46 Fairview Ave, Skowhegan, ME 04976 Phone: 207-474-5121 | |
Dr. David N Abisalih, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 61 Fairview Ave, Skowhegan, ME 04976 Phone: 207-858-8121 Fax: 207-474-3648 |